Cogent Biosciences, Inc. — Q2 2022 Form 10-Q
Reporting period: Three and six months ended June 30, 2022. Cogent is a clinical-stage biotechnology company developing precision medicines; it reported no product-sales revenue.
Financial performance and position
| Metric | Q2 / June 30, 2022 | Comparable period / prior year-end |
|---|---|---|
| Revenue | No product revenue | No product revenue |
| Research and development expense | $29.5 million | $12.4 million in Q2 2021 |
| General and administrative expense | $6.4 million | $4.9 million in Q2 2021 |
| Net loss | $34.9 million; $0.71 per share | $16.5 million; $0.43 per share in Q2 2021 |
| Six-month net loss | $65.6 million; $1.39 per share | $28.3 million; $0.77 per share in H1 2021 |
| Cash and cash equivalents | $325.6 million | $219.7 million at December 31, 2021 |
| Operating cash used | $54.8 million in H1 | $23.9 million in H1 2021 |
| Total assets / liabilities | $366.1 million / $46.7 million | $232.1 million / $17.9 million at December 31, 2021 |
For the six months, investing activities used $1.6 million and financing activities provided $162.3 million. The company reported an accumulated deficit of $336.5 million. Operating margins are not meaningful given the absence of product revenue and continuing development-stage losses.
No conventional borrowings are reported. Operating lease liabilities totaled $28.1 million, including $9.1 million current. The filing also describes a possible Boulder tenant-improvement loan of up to approximately $2.3 million; it does not clearly state that any amount had been drawn.
Material changes and financing
- Q2 net loss more than doubled year over year, primarily as R&D expense increased $17.1 million. R&D growth reflected bezuclastinib trials and manufacturing, discovery work, higher headcount and laboratory/facility costs.
- H1 total operating expenses rose to $67.3 million from $30.1 million. H1 net loss increased by $37.3 million year over year.
- In June, Cogent completed an underwritten offering of common shares and pre-funded warrants, generating approximately $161.9 million net. It issued 17.9 million common shares and warrants for 3.03 million additional shares.
- At June 30, common shares outstanding were 65.7 million; the filing states 90.6 million shares on a fully diluted and as-converted basis, including warrants and convertible Series A preferred stock. The offering and potential conversions are material dilution considerations.
Outlook, developments and risks
- Management said available cash was expected to fund operating and capital expenditure needs into 2025, based on current plans and assumptions. The financial-statement note separately states cash is expected to cover at least 12 months from issuance. Cogent expects significant future losses and may need additional funding; financing may be unavailable or dilutive, or require surrendering rights.
- In the ongoing Phase 2 APEX trial for advanced systemic mastocytosis, initial data as of May 24, 2022 showed all 11 treated patients achieved at least a 50% serum tryptase reduction (median reduction 89%); all eight assessed by bone marrow biopsy achieved at least a 50% mast-cell reduction. Management described early tolerability as favorable, but the dataset was small. Additional data were expected by year-end 2022.
- Cogent expected initial SUMMIT Phase 2 data in the first half of 2023 and PEAK Phase 3 lead-in data in the first half of 2023. It also planned to select an FGFR2 inhibitor candidate and file its first internally developed IND in the second half of 2023. These are forward-looking plans, not guarantees.
- A $2.5 million clinical milestone payment to Plexxikon was triggered by the PEAK study’s progression and paid in Q2. The license also provides for further clinical and regulatory milestones, royalties on potential sales, and certain sublicense payments.
- Clinical, regulatory, manufacturing, financing, intellectual-property and competition risks remain significant. The filing notes potential COVID-19-related disruption, though its financial impact was not then considered material. No material legal proceedings were reported; management reported effective disclosure controls and no material change in internal control over financial reporting.
Key facts for investors to verify
- Whether subsequent APEX, SUMMIT and PEAK results met the disclosed timelines and support the company’s efficacy and safety expectations.
- Cash runway against actual operating cash burn, clinical spending, and Boulder facility construction and lease commitments.
- Fully diluted share count, warrant exercise and preferred-stock conversion activity, and the potential effect of future equity issuance.
- Whether management’s “into 2025” runway estimate remains valid as trial enrollment, development costs and financing needs evolve.
- Future Plexxikon milestone obligations and other license terms that could affect cash requirements or economics of any approved product.